EGFR and non-small cell lung carcinoma: Our results are also apparently different from the findings of Hata et al., who described a median PFS of 5.0 months for EGFR-mutant NSCLC patients with p.T790M and of 2.7 months for those without p.T790M in the tissue biopsy obtained before TKI rechallenge [19].